Abstract
Randomized controlled clinical trials are being exposed to severe criticism in recent years. It is questioned if the use of placebos in such trials is ethically justified. This and other ethical problems will be discussed in this paper. Ethical problems include, besides the use of placebos. obtainment of informed consent and the belief in ‘treatment indifference’. Beforehand a historical overview is presented and the design of the randomized controlled clinical trial is explained. Some other types of clinical trials will also be touched upon.
Similar content being viewed by others
References
Brahams, D. (1982)Lancet I, 1028–1029;Ibidem (1982)II, 275.
Burkhardt, R., andG. Kienle (1978)Lancet II, 1356–1359;Ibidem (1981)Eur. J. Clin. Pharmacol. 20, 311–319.
Bywater, C.L. (1982)Lancet I, 1189.
Chalmers, T.C., J.B. Block andS. Lee (1972)N. Engl. J. Med. 287, 75–78.
Chalmers, T.C. (1974)Mt Sinai J. Med. 41, 753–759.
Clayton, D.G. (1982)Br. J. Clin. Pharmacol. 13, 469–480.
Declaration of Helsinki (as revised Tokyo, 1975) 18th World Medical Assembly (1964).
Ditchley Report: Report Conference Ditchley Foundations (1979)Eur. J. Clin. Pharmacol. 18, 129–134.
Editorial (1979)Lancet I, 534–535.
Editorial (1982)Lancet II, 78–79.
Editorial (1981)JAMA 246, 2481–2482.
Elkeles, A. (1982)Lancet I, 1189.
Fincke, M. (1977)Arzneimittelprüfung: strafbare Versuchsmethoden. C.F. Müller Juristischer Verlag, Heidelberg-Karlsruhe.
Forbes, J.F. (1981)Med. J. Aust. 1, 159–160.
Friedman, L.M., C.D. Furberg andD.L. Demets (1982)Fundamentals of clinical trials, 2nd ed. John Wright, PSG Inc. Boston-Briston-London.
Hayden, G.F., M.S. Kramer andR.I. Horwitz (1982)JAMA 247, 326–331.
Hill, A.B. (1963)Br. Med. J. 1, 1043–1049.
Horwitz, R.I., andA.R. Feinstein (1981)JAMA 246, 2455–2459.
Howard, J., andL. Friedman (1981)Clin. Pharmacol. Ther. 29, 561–569.
Jesdinsky, H.J. (1981)Eur. J. Clin. Pharmacol. 20, 235–236.
Joyce, C.R.B. (1982)Br. J. Clin. Pharmacol. 13, 313–318.
Lindeboom, G.A. (1961)Inleiding tot de geschiedenis der geneeskunde. Erven F. Bohn NV, Haarlem.
Machin, D., andW.E. Waters (1982)Lancet II, 275–276.
Meinertz, Th. (1982)Deutsche Apotheker Zeitung 122, 742–745
Rose, G. (1982)Br. J. Clin. Pharmacol. 13, 157–162.
Sacks, H., T.C. Chalmers andH. Smith (1982)Am. J. Med. 72, 233–240.
Shaw, L.W., andT.C. Chalmers (1970)Ann. N.Y. Acad. Sci. 169, 487.
Simmons, B. (1978)J. Med. Ethics 4, 172.
Spodick, D.H. (1982)JAMA 247, 2258–2260.
Von Essen, C.F. (1982)Lancet I, 1189.
Wade, O.L. (1982)Lancet II, 275.
Weatherall, D.J. (1982)J. Med. Ethics 8, 63–64.
Weinstein, M.C. (1974)N. Engl. J. Med. 291. 1278–1285.
Additional references
Schafer, A. (1982)N. Engl. J. Med. 307, 719–724.
Vere, D. (1981)J. R. Soc. Med. 74, 85–87.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Rosinga, W.M. Clinical trial under trial. Pharmaceutisch Weekblad Scientific Edition 5, 1–8 (1983). https://doi.org/10.1007/BF01959644
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01959644